Cargando…

Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome

Objective: Evidence suggests that food bioactives affect the epigenome to prevent pathological cardiac hypertrophy. Recently, we showed that emodin, an anthraquinone, attenuated pathological cardiac hypertrophy and histone deacetylase (HDAC) activity. However, we only examined the cardioprotective e...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Levi, Price, Tori, Hubert, Nathaniel, Moore, Julia, Shen, Yiqui, Athukorala, Maheshi, Frese, Steven, Martinez-Guryn, Kristina, Ferguson, Bradley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526847/
https://www.ncbi.nlm.nih.gov/pubmed/37759673
http://dx.doi.org/10.3390/biom13091274
_version_ 1785111081422684160
author Evans, Levi
Price, Tori
Hubert, Nathaniel
Moore, Julia
Shen, Yiqui
Athukorala, Maheshi
Frese, Steven
Martinez-Guryn, Kristina
Ferguson, Bradley S.
author_facet Evans, Levi
Price, Tori
Hubert, Nathaniel
Moore, Julia
Shen, Yiqui
Athukorala, Maheshi
Frese, Steven
Martinez-Guryn, Kristina
Ferguson, Bradley S.
author_sort Evans, Levi
collection PubMed
description Objective: Evidence suggests that food bioactives affect the epigenome to prevent pathological cardiac hypertrophy. Recently, we showed that emodin, an anthraquinone, attenuated pathological cardiac hypertrophy and histone deacetylase (HDAC) activity. However, we only examined the cardioprotective effects of emodin’s parent compound and not those of emodin metabolites or of emodin–gut microbiome interactions. The microbiome has emerged as a key player in chronic diseases such as metabolic and cardiac disease. Thus, we hypothesized that emodin could reverse hypertension-induced changes in microbial communities. Methods: Normo- and hypertensive (angiotensin II) C57/BL6 female mice were randomly assigned to receive a vehicle (Veh; DMSO:PEG 1:1) or emodin (Emod; 30 mg/kg) for 14 days. Body weights were collected pre- and post-treatment, and blood pressure was assessed via tail cuff. At the study’s end, the mice were euthanized and assessed for their heart weights. In addition, stool samples and cecal contents were collected to elucidate changes in the microbial populations using 16S rRNA sequencing. Lastly, the tissue was lysed, and RNA was isolated for qPCR. One-way ANOVA with Tukey’s post hoc test was performed unless otherwise specified, and p < 0.05 was considered significant. Results: Emodin significantly attenuated cardiac hypertrophy in the female mice. No significant changes were observed in body weight or systolic blood pressure in response to hypertension or emodin. Lastly, analysis suggests that hypertension altered the microbiome in the cecum and cecal content, with additional evidence to support that emodin affects gut microbiota in the feces and colon. Conclusions: Our data demonstrate that emodin attenuates pathological hypertrophy in female mice. Future research is needed to dissect if changes in the microbiome contributes to emodin-mediated attenuation in cardiac remodeling.
format Online
Article
Text
id pubmed-10526847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105268472023-09-28 Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome Evans, Levi Price, Tori Hubert, Nathaniel Moore, Julia Shen, Yiqui Athukorala, Maheshi Frese, Steven Martinez-Guryn, Kristina Ferguson, Bradley S. Biomolecules Communication Objective: Evidence suggests that food bioactives affect the epigenome to prevent pathological cardiac hypertrophy. Recently, we showed that emodin, an anthraquinone, attenuated pathological cardiac hypertrophy and histone deacetylase (HDAC) activity. However, we only examined the cardioprotective effects of emodin’s parent compound and not those of emodin metabolites or of emodin–gut microbiome interactions. The microbiome has emerged as a key player in chronic diseases such as metabolic and cardiac disease. Thus, we hypothesized that emodin could reverse hypertension-induced changes in microbial communities. Methods: Normo- and hypertensive (angiotensin II) C57/BL6 female mice were randomly assigned to receive a vehicle (Veh; DMSO:PEG 1:1) or emodin (Emod; 30 mg/kg) for 14 days. Body weights were collected pre- and post-treatment, and blood pressure was assessed via tail cuff. At the study’s end, the mice were euthanized and assessed for their heart weights. In addition, stool samples and cecal contents were collected to elucidate changes in the microbial populations using 16S rRNA sequencing. Lastly, the tissue was lysed, and RNA was isolated for qPCR. One-way ANOVA with Tukey’s post hoc test was performed unless otherwise specified, and p < 0.05 was considered significant. Results: Emodin significantly attenuated cardiac hypertrophy in the female mice. No significant changes were observed in body weight or systolic blood pressure in response to hypertension or emodin. Lastly, analysis suggests that hypertension altered the microbiome in the cecum and cecal content, with additional evidence to support that emodin affects gut microbiota in the feces and colon. Conclusions: Our data demonstrate that emodin attenuates pathological hypertrophy in female mice. Future research is needed to dissect if changes in the microbiome contributes to emodin-mediated attenuation in cardiac remodeling. MDPI 2023-08-22 /pmc/articles/PMC10526847/ /pubmed/37759673 http://dx.doi.org/10.3390/biom13091274 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Evans, Levi
Price, Tori
Hubert, Nathaniel
Moore, Julia
Shen, Yiqui
Athukorala, Maheshi
Frese, Steven
Martinez-Guryn, Kristina
Ferguson, Bradley S.
Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title_full Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title_fullStr Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title_full_unstemmed Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title_short Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
title_sort emodin inhibited pathological cardiac hypertrophy in response to angiotensin-induced hypertension and altered the gut microbiome
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526847/
https://www.ncbi.nlm.nih.gov/pubmed/37759673
http://dx.doi.org/10.3390/biom13091274
work_keys_str_mv AT evanslevi emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT pricetori emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT hubertnathaniel emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT moorejulia emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT shenyiqui emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT athukoralamaheshi emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT fresesteven emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT martinezgurynkristina emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome
AT fergusonbradleys emodininhibitedpathologicalcardiachypertrophyinresponsetoangiotensininducedhypertensionandalteredthegutmicrobiome